|1.||Iwamoto, Jun: 13 articles (01/2013 - 01/2002)|
|2.||Ringe, J D: 11 articles (03/2013 - 06/2000)|
|3.||Matsumoto, Toshio: 10 articles (04/2015 - 07/2010)|
|4.||Schacht, E: 10 articles (03/2013 - 01/2000)|
|5.||Takeda, Tsuyoshi: 10 articles (01/2011 - 01/2002)|
|6.||Sato, Yoshihiro: 9 articles (01/2013 - 07/2006)|
|7.||Uzawa, Mitsuyoshi: 8 articles (01/2013 - 01/2002)|
|8.||Shiraki, Masataka: 7 articles (07/2013 - 01/2004)|
|9.||Ito, Masako: 7 articles (11/2011 - 04/2002)|
|10.||Schacht, Erich: 7 articles (01/2011 - 07/2004)|
01/01/2000 - "Improved understanding of the pathogenesis of corticosteroid-induced osteoporosis and of the pharmacological effects of alfacalcidol in this type of iatrogenic bone loss as well as the results of specific animal models simulating bone loss in inflammatory diseases explain the favourable effects of alfacalcidol in this indication. "
10/01/1999 - "There is now a convergent body of evidence to suggest that alphacalcidol is a reasonable, safe, and effective option for the prevention of glucocorticoid-induced osteoporosis, provided that serum Ca is monitored on a regular basis."
09/01/2011 - "The subjects--a subgroup of a recent randomized, double-blind study comparing anti-fracture efficacy of ELD with alfacalcidol (ALF) - constituted 193 ambulatory patients with osteoporosis (189 postmenopausal women and 4 men aged 52-85 years, average ± SD: 70.9 ± 6.92 years) enrolled at 11 institutions. "
03/01/2004 - "In summary, alfacalcidol treatment increased cancellous and cortical bone mass and improved bone strength, resulting in the prevention of age-related bone loss in aged male rats. "
02/01/2003 - "Clinicians in Japan have accepted alfacalcidol as a remedy for osteoporosis. "
01/01/2000 - "Based on these results, alphacalcidol treatment appears to be effective in preventing glucocorticoid-induced bone loss in these patients by reducing secondary hyperparathyroidism and stimulating bone formation."
07/01/1996 - "Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis."
01/01/2011 - "This study was carried out to assess the efficacy of intravenous administration of alfacalcidol once weekly versus thrice weekly in patients with poorly controlled secondary hyperparathyroidism. "
10/01/2012 - "An open-labelled randomized study was performed comparing the effect of alfacalcidol versus no treatment in patients with CKD 4, secondary hyperparathyroidism and LVH. "
02/01/2013 - "These patients with secondary hyperparathyroidism had been on intravenous alfacalcidol twice or thrice per week and were followed up to 4 months (stage 1). "
|3.||Hypercalcemia (Milk Alkali Syndrome)
04/01/2002 - "Treatment of OVX mice with pharmacologic doses of alfacalcidol does not increase RANKL expression, whereas toxic doses that cause hypercalcemia markedly reduce the expression of RANKL. "
01/01/1989 - "The dosage of alfacalcidol ranged from 0.25 to 10 micrograms/day, and the medicine was administrated intermittently when the dosage exceeded 6 micrograms/day to prevent hypercalcemia. "
01/11/1986 - "[Severe hypercalcemia during treatment of Fahr's syndrome with alfacalcidol]."
10/01/1980 - "One alpha-hydroxyvitamin D3 (1 alpha-OH-D3) produced a hypercalcemia in parathyroidectomized, thyroparathyroidectomized and thyroparathyroidectomized nephrectomized rats. "
08/01/1989 - "When 1 alpha-hydroxyvitamin D3 (1 alpha-OH-D3) was administered orally to eight patients with leukemia, clinical conditions were improved in seven patients: four complete remissions (CR), one partial response (PR), and two minor responses (MR) without severe hypercalcemia. "
05/01/2005 - "Among the treatment groups, alfacalcidol significantly improved the hyperparathyroidism. "
12/01/1994 - "Oral bolus therapy and i.v. bolus therapy with alfacalcidol are equally effective in suppressing hyperparathyroidism. "
04/01/2008 - "This study was carried out to assess the efficacy of intravenous administration of alfacalcidol once weekly versus twice weekly in patients with severe hyperparathyroidism. "
06/01/2006 - "Feedback regulation of PTH with oral alfacalcidol therapy is efficient in the treatment of hyperparathyroidism. "
11/01/2004 - "Reversal of persistent hyperparathyroidism with the use of alfacalcidol may contribute to a decrease in skeletal morbidity."
|5.||Renal Insufficiency (Renal Failure)
03/01/2013 - "One important advantage of alfacalcidol may be that it is effective even in patients with mild-to-moderate renal insufficiency."
02/01/1995 - "Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone."
10/01/1983 - "Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure."
01/01/1983 - "Renal function and 1 alpha-hydroxyvitamin D3 in rabbits with normal renal function and renal insufficiency."
12/01/1995 - "We concluded that feedback regulation of PTH with oral alphacalcidol pulse therapy is effective in the treatment of hyperparathyroidism in children with renal failure prior to dialysis."
|3.||Alendronate (Alendronate Sodium)
|9.||Cholecalciferol (Vitamin D3)
|1.||Renal Dialysis (Hemodialysis)
|3.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|4.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|5.||Transplantation (Transplant Recipients)